Logo image of SAGE

SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis

NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock - Currency: USD

8.005  +0.22 (+2.76%)

Fundamental Rating

3

SAGE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While SAGE seems to be doing ok healthwise, there are quite some concerns on its profitability. SAGE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SAGE has reported negative net income.
SAGE had a negative operating cash flow in the past year.
SAGE had negative earnings in 4 of the past 5 years.
In the past 5 years SAGE reported 4 times negative operating cash flow.
SAGE Yearly Net Income VS EBIT VS OCF VS FCFSAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

1.2 Ratios

SAGE has a worse Return On Assets (-73.22%) than 67.08% of its industry peers.
With a Return On Equity value of -86.15%, SAGE perfoms like the industry average, outperforming 51.06% of the companies in the same industry.
Industry RankSector Rank
ROA -73.22%
ROE -86.15%
ROIC N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
SAGE Yearly ROA, ROE, ROICSAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

SAGE has a better Gross Margin (77.10%) than 83.80% of its industry peers.
SAGE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SAGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
SAGE Yearly Profit, Operating, Gross MarginsSAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SAGE has more shares outstanding
Compared to 5 years ago, SAGE has more shares outstanding
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SAGE Yearly Shares OutstandingSAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SAGE Yearly Total Debt VS Total AssetsSAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

SAGE has an Altman-Z score of -5.49. This is a bad value and indicates that SAGE is not financially healthy and even has some risk of bankruptcy.
SAGE has a Altman-Z score of -5.49. This is in the lower half of the industry: SAGE underperforms 61.80% of its industry peers.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.49
ROIC/WACCN/A
WACC10.3%
SAGE Yearly LT Debt VS Equity VS FCFSAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

SAGE has a Current Ratio of 7.42. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
SAGE has a Current ratio of 7.42. This is in the better half of the industry: SAGE outperforms 70.77% of its industry peers.
SAGE has a Quick Ratio of 7.42. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.42, SAGE is in the better half of the industry, outperforming 71.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
SAGE Yearly Current Assets VS Current LiabilitesSAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.08% over the past year.
SAGE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -52.30%.
The Revenue has been growing by 42.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)-52.3%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%-83.56%

3.2 Future

SAGE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.05% yearly.
Based on estimates for the next years, SAGE will show a very strong growth in Revenue. The Revenue will grow by 39.81% on average per year.
EPS Next Y45.65%
EPS Next 2Y26.16%
EPS Next 3Y20.61%
EPS Next 5Y14.05%
Revenue Next Year90.29%
Revenue Next 2Y80.32%
Revenue Next 3Y51.64%
Revenue Next 5Y39.81%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SAGE Yearly Revenue VS EstimatesSAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SAGE Yearly EPS VS EstimatesSAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAGE Price Earnings VS Forward Price EarningsSAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAGE Per share dataSAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as SAGE's earnings are expected to grow with 20.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.16%
EPS Next 3Y20.61%

More info and screens

0

5. Dividend

5.1 Amount

SAGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (4/25/2025, 10:18:09 AM)

8.005

+0.22 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)04-29 2025-04-29/bmo
Inst Owners79.77%
Inst Owner Change-0.18%
Ins Owners0.34%
Ins Owner Change2.26%
Market Cap492.15M
Analysts67.2
Price Target8.15 (1.81%)
Short Float %7.88%
Short Ratio3.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.28%
Min EPS beat(2)-1.61%
Max EPS beat(2)2.18%
EPS beat(4)1
Avg EPS beat(4)-1.76%
Min EPS beat(4)-7.14%
Max EPS beat(4)2.18%
EPS beat(8)2
Avg EPS beat(8)-8.21%
EPS beat(12)4
Avg EPS beat(12)-5.53%
EPS beat(16)6
Avg EPS beat(16)-4.33%
Revenue beat(2)1
Avg Revenue beat(2)-2.63%
Min Revenue beat(2)-12.99%
Max Revenue beat(2)7.74%
Revenue beat(4)2
Avg Revenue beat(4)6.19%
Min Revenue beat(4)-12.99%
Max Revenue beat(4)34.14%
Revenue beat(8)4
Avg Revenue beat(8)3.04%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)6
Avg Revenue beat(16)-5.56%
PT rev (1m)0.74%
PT rev (3m)-10.64%
EPS NQ rev (1m)0.67%
EPS NQ rev (3m)20.41%
EPS NY rev (1m)-0.9%
EPS NY rev (3m)10.02%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-11.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.93
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-6.59
EYN/A
EPS(NY)-3.58
Fwd EYN/A
FCF(TTM)-4.35
FCFYN/A
OCF(TTM)-4.35
OCFYN/A
SpS0.67
BVpS7.56
TBVpS7.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.22%
ROE -86.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.1%
FCFM N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z -5.49
F-Score2
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)40.51%
Cap/Depr(5y)28.52%
Cap/Sales(3y)4.11%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y45.65%
EPS Next 2Y26.16%
EPS Next 3Y20.61%
EPS Next 5Y14.05%
Revenue 1Y (TTM)-52.3%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%-83.56%
Revenue Next Year90.29%
Revenue Next 2Y80.32%
Revenue Next 3Y51.64%
Revenue Next 5Y39.81%
EBIT growth 1Y24.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.13%
EBIT Next 3Y21.59%
EBIT Next 5Y14.08%
FCF growth 1Y50.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.57%
OCF growth 3YN/A
OCF growth 5YN/A